Bupropion CYP2D6 Modulation for Dextromethorphan Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods fail to effectively increase dextromethorphan plasma levels and reduce adverse events in extensive metabolizers, leading to inefficiencies and adverse effects in dextromethorphan treatment.

Innovation Solution

Co-administration of bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion with dextromethorphan to enhance plasma levels and metabolic stability, and reduce dextrorphan plasma levels over multiple days.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If dextromethorphan is administered to extensive metabolizers, then cough suppression is achieved, but plasma levels are insufficient and adverse events occur

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidadverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Bupropion is introduced as an intermediary substance that inhibits the metabolism of dextromethorphan by CYP2D6 enzymes. This mediator allows extensive metabolizers to achieve therapeutic plasma levels of dextromethorphan without experiencing adverse effects from excessive metabolism, thus resolving the contradiction between therapeutic efficacy and harmful adverse events.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent changes the pharmacokinetic parameters of dextromethorphan by co-administering bupropion, which alters the metabolism rate and increases plasma concentration. This parameter change enables extensive metabolizers to achieve optimal drug levels without the harmful effects associated with rapid metabolism alone.

Inventive Principle:

Principle #35Parameter changes

2Reliability

If dextromethorphan plasma levels are increased, then therapeutic efficacy is improved, but adverse events increase

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidadverse events

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

Bupropion serves as a selective intermediary that targets the metabolism pathway without directly increasing dextromethorphan plasma levels through non-specific mechanisms. By specifically inhibiting CYP2D6, it achieves therapeutic enhancement while avoiding the adverse effects that would result from uncontrolled plasma level increases.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Duration of action of stationary object

If dextromethorphan is administered multiple times, then therapeutic effect is maintained, but frequency of doses increases

Engineering Contradiction:

Improveduration of actionVSAvoiddose frequency

Core Design Contradiction:

Duration of action of stationary objectVSProductivity

Solution Approach 1:

Bupropion is administered in advance to inhibit the metabolism of dextromethorphan before it is fully metabolized. This preliminary action extends the duration of action of dextromethorphan, allowing for reduced dose frequency while maintaining therapeutic effect, thus resolving the contradiction between duration of action and dose frequency.

Inventive Principle:

Principle #10Preliminary action

4Duration of action of moving object

If dextromethorphan plasma levels are increased, then metabolic lifetime is extended, but dextrorphan plasma levels increase

Engineering Contradiction:

Improvemetabolic lifetimeVSAvoiddextrorphan plasma levels

Core Design Contradiction:

Duration of action of moving objectVSObject-generated harmful factors

Solution Approach 1:

Bupropion acts as a selective intermediary that extends the metabolic lifetime of dextromethorphan while specifically avoiding the formation of dextrorphan. By targeting CYP2D6 inhibition, it achieves extended duration of action without generating the harmful dextrorphan metabolite, thus resolving this contradiction.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enhances dextromethorphan plasma levels, reduces adverse events, and decreases the frequency of doses required for effective treatment, while maintaining therapeutic efficacy.

Implementation Method 1

Bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion can be used to improve the therapeutic properties, such as in the treatment of neurological disorders, of dextromethorphan. Bupropion, hydroxybupropion, erythrohydroxybupropion, or threohydroxybupropion, or a metabolite or prodrug of any of these compounds, regardless of stereochemistry, can be effective in inhibiting or reducing the metabolism of dextromethorphan in some human beings.

Methodology Applied

Scientific EffectMetabolic inhibition: Enzyme

Data Source

PatentUS20250325539A1Bupropion as a modulator of drug activity

Publication Date: 2025.10.23 ANTECIP BIOVENTURES II LLC

AI summary

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.